Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 20/20 | 0.79 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.78 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279597 | 0.90 | NR1H2 (0.78) | NR1H2NR1H3RXRA | |
| SCHEMBL3278011 | 0.88 | NR1H2 (1.00) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3278004 | 0.88 | NR1H2 (1.00) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL1125648 | 0.87 | NR1H2 (0.72) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3278918 | 0.87 | NR1H2 (1.00) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3279436 | 0.84 | NR1H2 (0.85) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3279629 | 0.84 | NR1H2 (1.00) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3280411 | 0.84 | NR1H2 (1.00) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3278883 | 0.83 | NR1H2 (0.89) | NR1H2NR1H3RXRAPPARGPPARD | |
| SCHEMBL3279384 | 0.83 | NR1H2 (0.79) | NR1H2NR1H3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | claimed |
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | NR1H2 2/4885NR1H3 1/4885RXRA 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.